Q4FY21 revenue grew 40.3% YoY to | 259 crore amid 51.3% YoY growth in pharma CRAMS sales to | 137.7 crore. Specialty chemical CRAMS also posted robust growth of 35.1% YoY to | 109 crore. However, formulation sales fell 36% YoY to | 12.1 crore. EBITDA margins declined 566 bps YoY to 36.2% mainly due to lower gross margin performance (down 658 bps YoY at 64.7%). Subsequently, EBITDA grew 21.3% YoY to | 94 crore. PAT was up 12% YoY to | 83 crore. Delta vis-a-vis EBITDA was due to higher tax rate...